NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Deciphera Pharmaceuticals Inc (F: D05)

 
D05 Technical Analysis
5
As on 11th Aug 2025 D05 STOCK Price closed @ 50.75 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 26.49 & Strong Buy for SHORT-TERM with Stoploss of 13.99 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

D05STOCK Price

Open 50.77 Change Price %
High 51.00 1 Day 0.01 0.02
Low 50.35 1 Week 2.15 4.42
Close 50.75 1 Month 6.82 15.52
Volume 3577660 1 Year 36.61 258.91
52 Week High 49.75 | 52 Week Low 12.44
 
F Germany Most Active Stocks
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
ENB 47.60 -0.92%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
WDI 0.05 -37.50%
 
F Germany Top Gainers Stocks
JYR 1000000.00 10000000000.00%
JYR 1000000.00 10000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
0AI 11.30 14025.00%
0AI 11.30 14025.00%
SUE1 12.60 12500.00%
4CIA 3.17 2541.67%
 
F Germany Top Losers Stocks
TMLF 0.00 -100.00%
TMLF 0.00 -100.00%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
 
 
D05
Daily Charts
D05
Intraday Charts
Whats New @
Bazaartrend
D05
Free Analysis
 
D05 Important Levels Intraday
RESISTANCE52.00
RESISTANCE51.60
RESISTANCE51.35
RESISTANCE51.10
SUPPORT50.40
SUPPORT50.15
SUPPORT49.90
SUPPORT49.50
 
D05 Forecast August 2025
4th UP Forecast55.8
3rd UP Forecast54.18
2nd UP Forecast53.18
1st UP Forecast52.18
1st DOWN Forecast49.32
2nd DOWN Forecast48.32
3rd DOWN Forecast47.32
4th DOWN Forecast45.7
 
D05 Weekly Forecast
4th UP Forecast52.87
3rd UP Forecast52.19
2nd UP Forecast51.77
1st UP Forecast51.35
1st DOWN Forecast50.15
2nd DOWN Forecast49.73
3rd DOWN Forecast49.31
4th DOWN Forecast48.63
 
D05 Forecast2025
4th UP Forecast125.06
3rd UP Forecast101.23
2nd UP Forecast86.5
1st UP Forecast71.77
1st DOWN Forecast29.73
2nd DOWN Forecast15
3rd DOWN Forecast0.27
4th DOWN Forecast-23.56
 
 
D05 Other Details
Segment EQ
Market Capital 1694686976.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
D05 Address
D05
 
D05 Latest News
 
Your Comments and Response on Deciphera Pharmaceuticals Inc
 
D05 Business Profile
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. Address: 200 Smith Street, Waltham, MA, United States, 02451
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service